我国在研创新药数占全球约30%；阿斯利康达卓优获批上市

Policy Developments - The National Healthcare Security Administration held a training session on accelerating the construction of a long-term care insurance system, emphasizing the need for a unified and independent insurance model, multi-channel funding, and digital management to enhance service efficiency [2] Drug and Medical Device Approvals - Kangyuan Pharmaceutical received clinical trial approval for its Jin Zhen oral liquid to treat children's influenza, indicating a promising market outlook for this pediatric traditional Chinese medicine [4] - AstraZeneca's Datroway® was approved for use in treating hormone receptor-positive, HER2-negative breast cancer in adults who have previously undergone endocrine therapy and at least one line of chemotherapy, based on positive results from a global Phase III study [5] - Xianju Pharmaceutical's dexamethasone acetate tablets passed the consistency evaluation for generic drugs, which will enhance the company's market competitiveness [6] Financial Reports - Pian Zai Huang reported a 4.81% decline in total revenue to 5.379 billion yuan and a 16.22% decrease in net profit to 1.442 billion yuan for the first half of 2025, while advancing multiple new drug projects [8] - Wandong Medical achieved a 20.46% increase in revenue to 843 million yuan, but net profit fell by 39.46% to 51.3 million yuan, despite a 59.16% rise in R&D investment [9] - Huangshan Capsule reported a 3.66% increase in revenue to 244 million yuan and a 19.78% rise in net profit to 35.6 million yuan for the first half of 2025 [10] Capital Markets - Kexing Pharmaceutical announced plans to list on the Hong Kong Stock Exchange to enhance its international competitiveness and optimize its capital structure [12] - Tongce Medical acquired a 100% stake in Shanghai Congji Dental Clinic for 46 million yuan, aiming to enhance brand presence in the high-end market [13] Industry Developments - China's pharmaceutical industry ranks second globally, with approximately 30% of the world's innovative drugs under development, reflecting significant growth driven by policy, technology, and capital influx [15]